Advertisement
UK markets close in 3 hours 56 minutes

  • FTSE 100

    8,092.52
    +52.14 (+0.65%)
     

  • FTSE 250

    19,714.85
    -4.52 (-0.02%)
     

  • AIM

    754.89
    +0.20 (+0.03%)
     

  • GBP/EUR

    1.1664
    +0.0019 (+0.16%)
     

  • GBP/USD

    1.2512
    +0.0050 (+0.40%)
     

  • Bitcoin GBP

    50,984.97
    -2,223.73 (-4.18%)
     

  • CMC Crypto 200

    1,354.43
    -28.15 (-2.04%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.99
    +0.18 (+0.22%)
     

  • GOLD FUTURES

    2,340.70
    +2.30 (+0.10%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,966.39
    -122.31 (-0.68%)
     

  • CAC 40

    8,023.19
    -68.67 (-0.85%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Novartis says buys Ziarco Group to expand skin care portfolio

Reuters - UK Focus

ZURICH, Dec (Shanghai: 600875.SS - news) 16 (Reuters) - Novartis (IOB: 0QLR.IL - news) is buying privately held drugmaker Ziarco Group for an undisclosed sum to gain access to its investigational eczema medicine, the Swiss pharmaceutical giant said on Friday.

The acquisition adds UK-based Ziarco's once-daily oral H4 receptor antagonist, ZPL389, that is being developed for the chronic, itchy inflammatory skin condition to Novartis's existing portfolio of approved and investigational dermatological drugs.

"There is an unmet need for innovative, effective and safe oral treatment options for people living with eczema," Vasant Narasimhan, Novartis's head of drug development and chief medical officer, said in a statement. (Reporting by John Miller)